Johnson & Johnson to acquire Momenta over $6.5 billion buyout deal

19.08.2020 - Korneychuk Evgeniya
Johnson & Johnson to acquire Momenta over $6.5 billion buyout deal

On Wednesday, Johnson & Johnson (JNJ.N) announced that it would acquire Momenta Pharmaceuticals Inc (MNTA.O) in a buyout deal worth $6.5 billion.

The medical device company said that the acquisition deal would broaden its leadership in immune-mediated diseases and drive further growth.

According to Johnson & Johnson, its company would have access to Momenta’s experimental therapy called Nipocalimab.

“The agreement with J&J recognizes the value created by years of commitment and dedication to our mission by the many current and past Momenta employees. Programs such as Nipocalimab have the potential to improve the lives of countless patients suffering from autoimmune and fetal-maternal diseases,” Momenta’s President and Chief Executive Officer Craig Wheeler said.

“This acquisition provides strong value for our shareholders and ensures a level of investment in our exciting portfolio that will further enhance its potential for patients. I believe J&J is the right company to advance our portfolio of novel drug candidates for autoimmune and rare diseases. J&J’s leadership in immunology, extensive capabilities, and global reach, as well as its alignment with our vision of pioneering therapies for complex diseases, is a strong fit for our company and our portfolio,” he added.

Momenta’s shares went up by 68% at $51.98 in the afternoon trading.

Risk disclaimer "PROMETHEUS LTD – Trust Company Complex, Ajeltake Road, Ajeltake Island, Majuro, Republic of the Marshall Islands MH96960 is a financial services institution outside the European Union Area, which is subject to the supervision of the IFMRRC Certificate 0395 AA V0155 Trading in Forex/ CFDs and Other Derivatives is highly speculative and carries a high level of risk. It is possible to lose all your capital. 70% of trading deals can be unprofitable. These products may not be suitable for everyone and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. This Website may contain information in particular regarding financial services and products that could be regarded b a E.U. supervisory authority as an offer of financial services targeted in Europe. ESMA intervention measures do not apply to customers of PROMETHEUS LTD and it is your responsibility to choose a company which is most suitable for your trading needs. By clicking continue you confirm that you have read, understood and agree to the risk disclosures, terms of service, cash policies, privacy policies and this notice and that you are visiting this website on your own initiative, without any encouragement whatsoever from umarkets.net or PROMETHEUS LTD." Cookies notification: We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we assume that you are happy with it. Read more. Continue
×

Help with deposit?